Product Information
HORIZANT ER 300 MG TABLET is a brand product labeled by Azurity Pharmaceuticals Inc., priced at $17.9282 per EA under NDC 53451010301. Its NADAC has been published 607 times since Feb 18, 2015.
FDA first approved this application on Apr 6, 2011.
Strength
300 mg/1
Manufacturer
Azurity Pharmaceuticals Inc.NDC
53451010301
Classification
Brand
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GABAPENTIN ENACARBILApproval Type
New Drug (NDA)
FDA Application
NDA022399FDA Approved
4/6/2011
On Market Since
5/1/2013
Pharmacological Classes
Price Statistics
The NADAC for HORIZANT ER 300 MG TABLET has been published 607 times since Feb 18, 2015, and over the history we have for it it has risen 137.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $17.9282 per EA |
|---|---|
| All-time high | $17.9791 (Jun 11, 2025) |
| All-time low | $7.5545 (Feb 18, 2015) |
| 52-week high | $17.9469 |
| 52-week low | $17.9214 |
| Median price | $13.6544 |
| Average price | $13.7689 |
| Largest weekly change | +18.0% (Jan 13, 2016) |
| Weeks tracked | 607 |
| Tracking since | Feb 18, 2015 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the gabapentin enacarbil market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Azurity Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
gabapentin enacarbil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of HORIZANT ER 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for HORIZANT ER 300 MG TABLET, manufactured by Azurity Pharmaceuticals Inc., is $17.9282 per EA (NDC 53451010301), effective Sep 30, 2026.
How has the price of HORIZANT ER 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for HORIZANT ER 300 MG TABLET has risen 137.3%. It has been tracked across 607 weekly CMS publications since Feb 18, 2015.
What are the highest and lowest recorded NADAC prices for HORIZANT ER 300 MG TABLET?
Since Feb 18, 2015, the NADAC for HORIZANT ER 300 MG TABLET has ranged from a low of $7.5545 (Feb 18, 2015) to a high of $17.9791 (Jun 11, 2025), with a median of $13.6544 per EA.
Are there cheaper alternatives to HORIZANT ER 300 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of HORIZANT ER 300 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures HORIZANT ER 300 MG TABLET?
HORIZANT ER 300 MG TABLET (NDC 53451010301) is labeled by Azurity Pharmaceuticals Inc., and CMS classifies it as a brand product.